Idiopathic Membranous Nephropathy (IMN) Epidemiology Insights & Forecast, 2032

DUBLIN, July 28, 2023 /PRNewswire/ -- The "Idiopathic Membranous Nephropathy - Epidemiology Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.

This comprehensive report provides valuable insights into the epidemiology of Idiopathic Membranous Nephropathy (IMN). It explores the prevalence and trends of IMN in the United States, EU4 countries (Germany, France, Italy, Spain), the United Kingdom, and Japan. Key aspects covered include disease background, diagnosis, biomarkers, and an in-depth analysis of historical and forecasted data.

Report Scope

The report highlights significant findings related to IMN epidemiology. In 2022, the United States accounted for the highest proportion of prevalent IMN cases, followed by EU4 countries and Japan. The forecasted patient pool for IMN is expected to increase by 2032 in these regions. It also provides insights into the prevalence rates and distribution of IMN by antigens in each region. The report addresses the risks and burdens associated with IMN.

Report Highlights and Key Questions Answered

The report presents a 10-year forecast of IMN and covers aspects such as prevalence, antigens, and growth opportunities across the seven major markets. It answers key questions about the risk and burden of IMN, historical patient pools, forecasted patient pools, growth opportunities, and the country with the highest IMN cases during the forecast period.

This report offers a comprehensive understanding of the epidemiology of Idiopathic Membranous Nephropathy (IMN). It equips readers with crucial insights and analysis, enabling them to make informed decisions and strategies related to IMN research, treatment, and patient care.

Key Findings

• In 2022, among the 7MM, the United States accounted for the highest proportion (~41%) of prevalent cases of IMN.
• EU4 and the UK accounted for ~24,000 cases of IMN in 2022, which is expected to increase by 2032.
• In 2022, Japan accounted for ~23% of the total prevalent IMN cases among the 7MM countries. Approximately 16,000 IMN cases were observed in Japan in 2022.
• Among EU4 and the UK, France had the lowest number of prevalent cases of IMN at ~4,100 cases in 2022. As per this 's estimates, these cases are expected to increase by 2032.
• Approximately one-third of participants with IMN undergo spontaneous remission. In 2022, the addressable pool of IMN included ~47,000 cases in the 7MM.
• About 80% of MN cases are renal limited (primary MN), and 20% are associated with other systemic diseases or exposures (secondary MN).
• In the United States, PLA2R and THSD7A antigens were observed in ~80% and ~3% of IMN patients, respectively.

Key Topics Covered

1. Key Insights

2. Report Introduction

3. IMN Epidemiology Overview at a Glance
3.1. Patient Share (%) Distribution of IMN in 2019
3.2. Patient Share (%) Distribution of IMN in 2032

4. Executive Summary of IMN

5. Disease Background and Overview
5.1. Introduction
5.2. Sign and Symptoms
5.3. Classification
5.4. Causes
5.5. Pathophysiology
5.6. Diagnosis
5.7. Biomarkers

6. Methodology

7. Epidemiology and Patient Population
7.1. Key Findings
7.2. Assumptions and Rationale
7.3. Prevalence of Idiopathic Membranous Nephropathy in the 7MM
7.4. The United States
7.4.1. Prevalence of Idiopathic Membranous Nephropathy
7.4.2. Prevalence of Idiopathic Membranous Nephropathy by Antigens
7.5. EU4 and the UK
7.5.1. Prevalence of Idiopathic Membranous Nephropathy
7.5.2. Prevalence of Idiopathic Membranous Nephropathy by Antigens
7.6. Japan
7.6.1. Prevalence of Idiopathic Membranous Nephropathy
7.6.2. Prevalence of Idiopathic Membranous Nephropathy by Antigens

8. Appendix
8.1. Bibliography
8.2. Report Methodology

For more information about this report visit https://www.researchandmarkets.com/r/2p1rfm

About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.

Media Contact:

Research and Markets
Laura Wood, Senior Manager
[email protected]

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

Logo: https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

SOURCE Research and Markets